LGND
Ligand Pharmaceuticals Incorporated
NASDAQ: LGND · HEALTHCARE · BIOTECHNOLOGY
$224.86
-3.21% today
Updated 2026-04-29
Market cap
$2.73B
P/E ratio
36.74
P/S ratio
10.17x
EPS (TTM)
$6.12
Dividend yield
—
52W range
$99 – $247
Volume
0.2M
Ligand Pharmaceuticals Incorporated (LGND) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$224.86
12-Month target
$185.80
2030 Target
—
Intrinsic (DCF)
$272.89
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.2B | $0.2B | $0.1B | $0.2B | $0.3B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 46.40%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.